GlassScriptPhysician profile
Laura Clark Windham
NPI 1902886211
$221.92
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $27.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $38.79 | 2019 | |
| Kaleo, INC. | $32.67 | 2019 | |
| Sobi, INC | $25.33 | 2019 | |
| Roche Diagnostics Corporation | $23.10 | 2019 | |
| Genentech USA, INC. | $16.66 | 2019 | |
| Cranial Technologies, INC | $16.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.30 | 2019 | |
| Glaxosmithkline, LLC. | $14.93 | 2020 | |
| Rhodes Pharmaceuticals L.P. | $14.91 | 2019 | |
| Merck Sharp & Dohme LLC | $12.21 | 2020 | |
| Pfizer INC. | $11.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Windham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.